CVS Health (NYSE:CVS – Get Free Report) had its price objective increased by analysts at JPMorgan Chase & Co. from $80.00 to $81.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the pharmacy operator’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 23.95% from the stock’s previous close.
Several other equities analysts have also issued reports on the stock. Wells Fargo & Company lifted their target price on shares of CVS Health from $68.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Evercore ISI raised their price target on CVS Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 27th. Mizuho reduced their price objective on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. UBS Group cut their target price on CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 11th. Finally, Edward Jones upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $70.00.
Get Our Latest Stock Report on CVS
CVS Health Trading Down 0.7 %
CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. On average, equities research analysts predict that CVS Health will post 5.14 EPS for the current fiscal year.
Institutional Investors Weigh In On CVS Health
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. DCM Advisors LLC raised its holdings in CVS Health by 15.5% during the fourth quarter. DCM Advisors LLC now owns 81,530 shares of the pharmacy operator’s stock valued at $3,435,000 after acquiring an additional 10,920 shares during the period. Orion Capital Management LLC bought a new stake in CVS Health during the 4th quarter valued at approximately $54,000. McIlrath & Eck LLC lifted its holdings in CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 174 shares in the last quarter. Novem Group bought a new position in CVS Health in the 4th quarter worth approximately $562,000. Finally, NCM Capital Management LLC grew its holdings in CVS Health by 184.2% during the 4th quarter. NCM Capital Management LLC now owns 11,225 shares of the pharmacy operator’s stock valued at $504,000 after buying an additional 7,276 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.
CVS Health Company Profile
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Articles
- Five stocks we like better than CVS Health
- Do ETFs Pay Dividends? What You Need to Know
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Upcoming IPO Stock Lockup Period, Explained
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
- How to Calculate Options Profits
- Analysts See Buying Opportunity in NVIDIA Before Earnings
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.